0000000000305908

AUTHOR

Rafael Ruiz-salmerón

showing 3 related works from this author

Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.

2019

The Collaborative Working Group “Noma Project Team”.

0301 basic medicinelcsh:Immunologic diseases. Allergycritical limb ischemiaCell typecost-effectivecell-based therapyImmunologyBioinformaticsCell therapy03 medical and health sciences0302 clinical medicineImmunology and AllergyMedicineOriginal Researchclinical trialsdiabetesbusiness.industryMesenchymal stem cellType 2 Diabetes MellitusCritical limb ischemiacellular medicamentsClinical trial030104 developmental biologyStem cellmedicine.symptombusinesslcsh:RC581-607030215 immunologyAdult stem cell
researchProduct

TCT-350 Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First 400 Subjects at 12-month Follow-up of t…

2018

The aim of this registry is to investigate the clinical performance and long-term safety of the Resorbable Magnesium Scaffold (Magmaris) (BIOTRONIK AG, Buelach, Switzerland) in a real-world setting. Up to 2,054 subjects in up to 120 clinical sites in Europe, Asia, and Asia-Pacific countries will

Scaffoldmedicine.medical_specialtybusiness.industry0206 medical engineeringClinical performance02 engineering and technology030204 cardiovascular system & hematology020601 biomedical engineering03 medical and health sciences0302 clinical medicineInternal medicineCohortMedicineCardiology and Cardiovascular MedicinebusinessMonth follow upJournal of the American College of Cardiology
researchProduct

Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.

2020

[This corrects the article DOI: 10.3389/fimmu.2019.01151.].

lcsh:Immunologic diseases. Allergycritical limb ischemiamedicine.medical_specialtyclinical trialsdiabetesbusiness.industrycost-effectivecell-based therapyImmunologyType 2 Diabetes MellitusCorrectionCritical limb ischemiamedicine.diseasecellular medicamentsCell therapyClinical trialDiabetes mellitusInternal medicinemedicineImmunology and Allergymedicine.symptombusinesslcsh:RC581-607
researchProduct